Anti-MMAF monoclonal antibody, Biotin

Monomethyl Auristatin F (MMAF) is a semisynthetic analog of Dolastatin 10, widely used in anticancer drug development. It exerts potent cytotoxic effects by inhibiting the polymerization of tubulin, thereby blocking cell mitosis. MMAF is particularly suitable for antibody-drug conjugates (ADCs) as a cytotoxic payload, allowing for targeted cancer therapy in combination with monoclonal antibodies. Compared to Monomethyl Auristatin E (MMAE), MMAF possesses different physicochemical properties, such as lower cell membrane permeability and reduced systemic toxicity, making it advantageous in certain therapeutic contexts. The molecular structure of MMAF consists of a pentapeptide chain, featuring a charged C-terminal phenylalanine residue (Phe). This unique charged structure enhances the hydrophilicity of MMAF, preventing it from easily crossing cell membranes like MMAE. The uncharged terminus of MMAE allows for greater membrane permeability, which correlates with higher cytotoxicity but also leads to increased systemic toxicity. In contrast, MMAF's hydrophilicity reduces its intracellular toxicity while improving stability and safety in plasma. The charged structure of MMAF also facilitates stronger binding to proteins, enabling effective targeting of cancer cells through ADCs. This characteristic is fundamental to MMAF's widespread use as a cytotoxic payload in ADCs. Both MMAF and MMAE are derivatives of Dolastatin 10 and share structural similarities; however, they exhibit significant differences in cytotoxicity, membrane permeability, and systemic toxicity. MMAE's uncharged structure allows for easier membrane penetration and higher cytotoxicity, but it also presents higher systemic toxicity and lower safety. In contrast, MMAF's charged C-terminus hinders easy membrane penetration, resulting in lower toxicity while being more hydrophilic and suitable for antibody conjugation in ADC development. These properties position MMAF favorably in cancer treatments requiring long-term therapy and higher safety control, especially in ADCs for hematological malignancies.

Figure 1. Structure of Monomethyl Auristatin F (MMAF) (Park M-H, et al., 2019)

The primary mechanism of action for MMAF is the binding to tubulin, preventing its polymerization and disrupting the dynamic equilibrium of microtubules. This inactivation of microtubules hinders cell mitosis, causing cells to arrest at the G2/M phase and ultimately leading to apoptosis. Given the rapid division characteristics of cancer cells, MMAF's mechanism is particularly effective against them. As an antimitotic drug, MMAF demonstrates stronger cytotoxicity than its natural derivative, Dolastatin 10. Furthermore, unlike MMAE, MMAF is better suited for treatment scenarios that require low permeability, such as localized tumor therapies. Antibody-drug conjugates (ADCs) represent an innovative therapeutic approach that delivers small molecule toxins to cancer cells through targeted antibodies. MMAF is one of the most commonly used payloads in ADCs. In ADC design, monoclonal antibodies target specific antigens on the surface of cancer cells, while MMAF is linked to the antibody via a linker, allowing for the release of MMAF upon cellular uptake, leading to cancer cell apoptosis. Several MMAF-based ADCs have been developed and are currently undergoing clinical trials. For instance, Brentuximab vedotin was the first MMAF-based ADC to receive FDA approval and is widely used in treating Hodgkin lymphoma and systemic anaplastic large cell lymphoma. This drug targets CD30-expressing cancer cells, utilizing MMAF's cytotoxic action to induce cancer cell death. Additionally, studies indicate that MMAF-ADCs demonstrate potent antitumor activity across various tumor models, particularly in the treatment of hematological malignancies. MMAF is primarily metabolized through the hepatic enzyme system, and research has identified four main types of metabolites, including mono-oxidation, demethylation, and the removal of specific structural units. Among these, the demethylated metabolite is the predominant product. The metabolic profiles of MMAF show differences between rat and human liver microsomes, likely due to interspecies variations in metabolic enzymes. In preclinical studies, MMAF's safety has been extensively validated, showing good tolerance even at high doses. Compared to MMAE, MMAF significantly reduces systemic toxicity, making it suitable for longer cancer treatment durations.

MMAF has shown extensive clinical potential in the application of antibody-drug conjugates. Various MMAF-based ADCs have entered clinical trials, demonstrating significant efficacy in treating both solid tumors and hematological malignancies. For example, SGN-35 (Brentuximab vedotin) has demonstrated outstanding effectiveness in recurrent Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Furthermore, the application of MMAF-ADCs in solid tumors like breast cancer and gastric cancer has also been clinically validated. With the continuous development of linker technologies, such as the introduction of non-cleavable linkers, the therapeutic index of MMAF-ADCs has significantly improved, offering broader prospects for MMAF in future clinical applications. Despite the broad application potential of MMAF in ADCs, its development faces several challenges. For instance, the low membrane permeability of MMAF may limit its activity in certain cancer cells. Additionally, the complexity of MMAF's metabolism and interspecies differences pose challenges for clinical application. Future research may require further optimization of MMAF's structure or improvements in linker technology to enhance its permeability and potency in specific cancer cells. In summary, MMAF, as an auristatin-class antimitotic drug, demonstrates extensive application potential in the development of antibody-drug conjugates due to its unique structure and mechanism of action. Compared to MMAE, MMAF exhibits lower systemic toxicity and better safety due to its charged C-terminus, making it suitable as a cytotoxic payload for various cancer treatments. With the continuous advancement of linker technology, MMAF is expected to play an increasingly important role in future cancer therapies.

MMAF antibody
clone 3F3 monoclonal antibody
biotinylated MMAF antibody
MMAF mAb (monoclonal antibody)
anti-MMAF